Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go

Meng Lv; Xiao-Jun Huang

doi:10.1186/1756-8722-5-10

Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go

J Hematol Oncol. 2012 Mar 18:5:10. doi: 10.1186/1756-8722-5-10.

Authors

Meng Lv¹, Xiao-Jun Huang

Affiliation

¹ Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, No. 11 Xizhimen South Street, Beijng 100044, China.

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective and sometimes the only curative therapy for patients with certain hematological diseases. Allo-HSCT has been practiced in China for approximately 30 years, and great improvements have been made within the past decade, particularly in fields such as the haploidentical HSCT system, strategies to overcome relapse and GVHD, and modified HSCT for elderly patients. This review will describe the current situation and provide a prospective of these unique aspects of Allo-HSCT in China.

Publication types

Evaluation Study
Research Support, Non-U.S. Gov't
Review

MeSH terms

Age Factors
China
Graft vs Host Disease / prevention & control
Graft vs Host Disease / therapy
Hematopoietic Stem Cell Transplantation / ethnology
Hematopoietic Stem Cell Transplantation / methods*
Hematopoietic Stem Cell Transplantation / trends*
Humans
Models, Biological
Transplantation Conditioning / methods
Transplantation, Homologous